Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease (AMSC-DSD-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03827096
Recruitment Status : Terminated (Primary endpoint (Safety) has been achieved)
First Posted : February 1, 2019
Last Update Posted : January 18, 2020
Sponsor:
Collaborator:
Department of Spine Surgery, University Hospital Motol, Prague, Czech Republilc
Information provided by (Responsible Party):
Bioinova, s.r.o.

Brief Summary:
Subjects in whom a posterolateral fusion surgery has been planned and who meet the inclusion and exclusion criteria were proposed to receive a single-dose AMSC treatment, in order to assess its safety and efficacy on posterolateral interbody fusion. After the surgery, the subjects were followed up as out-patients during 5 study visits for 12 months in total.

Condition or disease Intervention/treatment Phase
Degenerative Disc Disease Drug: Suspension of human autologous MSC 3P in 1.5 ml Phase 1 Phase 2

Detailed Description:

Following informed consent collection at the screening visit and verification of all inclusion and exclusion criteria, eligible patients will undergo the procedure of bone marrow cell aspiration from iliac crest for the purpose of receiving autologous multipotent mesenchymal stem cells. The cells will be cultivated for 3 passages (for 3 - 4 weeks) in order to expand them to sufficient quantity. Suspension of the cultured AMSC will then be sterilely packed and transported to the surgery site. During the posterolateral spine fusion operation, 1.5 ml of cell suspension will be mixed with 5 cc of beta-tricalcium phosphate foam (Vitoss™, Orthovita) and 3.5 ml of patient's blood, and inserted between the transverse processes of the lumbar spine.

All subjects will be hospitalized and followed up as per standard medical care rules used in the investigational site hospital for this type of intervention.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease to Assess the Safety and the Efficacy
Actual Study Start Date : August 27, 2013
Actual Primary Completion Date : December 14, 2016
Actual Study Completion Date : December 14, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Human AMSC (passage 3) 3P in 1.5 mL
Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL
Drug: Suspension of human autologous MSC 3P in 1.5 ml
During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
Other Name: hAMSC




Primary Outcome Measures :
  1. Safety: To demonstrate absence of complications at the site of spinal fusion [ Time Frame: 1 year ]

    Complications at the site of spinal fusion and other treatment-related adverse events will be recorded in ten patients at Visits I through VII. All adverse events (AEs) will be classified by seriousness, severity and relationship to hAMSC application.

    All AEs will be collected as symptoms spontaneously reported by the patient, clinically relevant changes and abnormalities observed by the Investigator (clinically significant laboratory measurements confirmed by repeated measurement, results of physical examinations) Intensity

    The following 3-point rating scale will be used for rating of the intensity of each AE:

    Mild: Awareness of signs or symptoms, but no disruption of usual activity Moderate: Event sufficient to affect usual activities (disturbing) Severe: Inability to work or perform usual activities (unacceptable)



Secondary Outcome Measures :
  1. Efficacy: To assess the quality of life determined by Oswestry Questionnaire. [ Time Frame: 1 year ]
    The quality of life determined by Oswestry Questionnaire will be recorded in ten patients at Visits II, and IV through VII. The test has 10 sections and maximum score is 50 points; change from the baseline valie will be recorded. The points are then transferred into percentage and interpreted in a standard way when 0-20% means minimal disability while 81-100% means bed-bound condition. Minimum detectable change (90 % confidence) is 10 % (5 points).

  2. Efficacy: To assess the quality of spinal fusion by X-ray imaging [ Time Frame: 1 year ]

    The quality of spinal fusion will be measured by X-ray imaging at Visits V and VII. Dynamic X-ray of the lumbar spine will be performed at 3 and 12 months following the surgery and hAMSC application to measure the angle of the spine movement in the fusion area. The angle will be recorded in degrees. The movements above 10 degrees will beregarded as "unstable".

    The bone fusion morphology will be evaluated based on the following scale:

    1. Cyst or pseudo-cyst formation
    2. Fusion not visible
    3. Pseudo-joint (or false joint) development
    4. Low degree of bone fusion
    5. High degree of bone fusion

  3. Efficacy: To assess the quality of spinal fusion measured by computed tomography (CT). [ Time Frame: 1 year ]

    The quality of spinal fusion will be measured by CT in ten patients at Visits V and VII.

    The density will of the fusion will be expressed as % on a linear scale between two standardized measuring points: soft tissue= 0%, vertebral arch= 100%.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. established diagnosis of spinal degenerative disease indicated for lumbar spine surgery,
  2. patients indicated for fusion therapy,
  3. patients between 18-55 years, both sexes,
  4. patients able to provide written informed consent.

Exclusion Criteria:

  1. previous lumbar spine surgery in the same segment of the spine, in order to achieve vertebral fusion,
  2. osteoporosis,
  3. diabetes mellitus,
  4. pregnancy or breastfeeding,
  5. women of childbearing potential not using effective contraception (established oral contraception, intrauterine device, ligation of the uterine tube) including proven contraceptive measures taken by their sexual partners,
  6. fertile men not using proven contraceptive measures including effective contraception method in their partner (established oral contraception, intrauterine device, ligation of the uterine tube),
  7. coagulopathy,
  8. malnutrition, primary biliary cirrhosis,
  9. skin infection at the site of bone marrow aspiration or at the site of spinal fusion,
  10. gastrostomy,
  11. any significant medical condition that would compromise the safety of the patient (e.g. recent myocardial infarction, congestive heart failure, renal failure, liver failure, systemic infection, recurrent thromboembolic disease .....),
  12. alcohol or drug abuse,
  13. cancer (compulsory clinical oncological screening),
  14. ongoing or recent (last 3 months) systemic corticosteroid or immunosuppressive therapy.
Layout table for additonal information
Responsible Party: Bioinova, s.r.o.
ClinicalTrials.gov Identifier: NCT03827096    
Other Study ID Numbers: AMSC-DSD-001
First Posted: February 1, 2019    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The data will be published

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Intervertebral Disc Degeneration
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases